Cambridge Cognition expands into Chinese market with new strategic partnership

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China.  Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare to commercialise the Company’s suite of leading cognitive assessment tools in China for both the pharmaceutical and healthcare markets.

The strategic partnership provides Cambridge Cognition with an efficient and low risk geographic expansion whilst leveraging the Company’s recent projects to go live in an Amazon Web Service (“AWS”) data centre in China and implement a range of Chinese languages.  Cambridge Cognition will be paid through a mix of milestone payments and royalties.  As well as a commercial license, the partnership includes the opportunity to collaborate on co-developments to improve both companies’ solutions. 

China is the second most active clinical trial market in the world after the US, having hosted nearly 10,000 industry sponsored trials in the last five years with 14% being in Central Nervous System conditions1. The healthcare market opportunity in China for cognitive impairment diagnostics may also be considerable with nearly 40 million people affected by mild cognitive impairment and nearly 10 million living with Alzheimer’s disease2.

Cambridge Cognition has been laying the groundwork to successfully capitalise on this significant market opportunity since 2019 by establishing a dedicated service in the region delivered from a secure cloud infrastructure provided by AWS in China; developing task variants in the most common spoken (Cantonese and Mandarin) and written (Chinese simplified) languages; and building on an existing relationship with one of the leading Chinese universities, Fudan University, Shanghai.

Echo Chen, Chief Executive Officer of Luca Healthcare, said:

“We are absolutely thrilled to be working with a great team and the most validated cognition assessment tool in the world. Luca’s mission is to make healthcare more affordable and more accessible; this partnership certainly gives us an opportunity to do that for those impacted by neurodegenerative disorders in China.”

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“The Chinese pharmaceutical and healthcare markets offer a significant commercial opportunity for Cambridge Cognition, and we have partnered with Luca Healthcare to capitalise on this. The team at Luca Healthcare have impressed us with their speed to commercialise other digital healthcare solutions, working with leading pharmaceutical companies in the region and, as a result, building a fast growth business.”

References

1.    GlobalData. Industry Sponsored Trials in China 17/11/2017 – 17/11/2022.

2.    The China Alzheimer’s Report 2022, BMJ General Psychiatry, Vol 35-1

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions of Clinpal

Cambridge Cognition Holdings

Cambridge Cognition investor webinar on 3 May 2023

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will be announcing the Company’s preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased

Cambridge Cognition Holdings

Cambridge Cognition Holdings confirm date for year end results

Cambridge Cognition Holdings Plc (LON: COG), which develops and markets digital solutions to assess brain health, has confirmed that it will announce the Company’s preliminary financial results for the year ended 31 December 2022, on Wednesday 3 May 2023.

Cambridge Cognition Holdings

Cambridge Cognition wins two contracts worth over £2.1 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won two sizeable contracts, together worth over £2.1 million, to provide the Company’s CANTAB® cognitive assessments and electronic

Cambridge Cognition Holdings

Cambridge Cognition 25% growth in revenues to £12.6 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 ·         Revenue ahead of

Cambridge Cognition Holdings

Cambridge Cognition acquires Winterlight Labs Inc

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis.  The total consideration for the Acquisition is

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022. The Company followed its strong performance in 2021 with a 31%

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

No more posts to show